Compare MLKN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | CDNA |
|---|---|---|
| Founded | 1905 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1994 | 2007 |
| Metric | MLKN | CDNA |
|---|---|---|
| Price | $14.93 | $20.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 619.0K | ★ 733.7K |
| Earning Date | 03-25-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | 0.05 |
| Revenue | ★ $3,669,900,000.00 | $48,324,000.00 |
| Revenue This Year | $5.94 | $16.01 |
| Revenue Next Year | $3.78 | $11.31 |
| P/E Ratio | ★ $15.00 | $413.00 |
| Revenue Growth | 1.14 | ★ 18.93 |
| 52 Week Low | $13.77 | $10.96 |
| 52 Week High | $23.18 | $23.24 |
| Indicator | MLKN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 51.30 |
| Support Level | $13.81 | $16.63 |
| Resistance Level | $16.19 | $21.20 |
| Average True Range (ATR) | 0.61 | 1.34 |
| MACD | -0.13 | -0.16 |
| Stochastic Oscillator | 13.00 | 48.05 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.